Key facts
- It has raised $33.3M; the latest was Early Stage VC ($23.3M) in Sep 2025.
- Notable investors include MedTech Innovator, Qiming Venture Partners, 5Y Capital, K2VC, BioTools Innovator — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Aureka Biotechnologies
- ·The full record, as it builds
Funding rounds
No funding rounds for Aureka Biotechnologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aureka Biotechnologies
Developer of a therapeutic discovery platform intended to digitalize therapeutic design at scale. The company leverages cutting-edge machine learning and artificial intelligence to identify and design potential drug candidates, enabling the pharmaceutical industry to develop novel treatments to reduce cost and time.
- Sector
- Healthcare
- HQ
- Laguna Hills, CA, United States
- Founded
- 2023
- Employees
- 23
- Website
- aurekabio.com/
- Ownership
- Privately Held (backing)
Aureka Biotechnologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aureka Biotechnologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aureka Biotechnologies in its N-PORT filings yet. We sweep new filings monthly.